guest ::
| Home > Publications database > Anatomical outcome after brachytherapy with bi-nuclide (Ru-106/Iodine-125) plaques in large uveal melanomas. |
| Home > Publications database > Anatomical outcome after brachytherapy with bi-nuclide (Ru-106/Iodine-125) plaques in large uveal melanomas. |
| Journal Article | DKFZ-2025-01619 |
; ; ; ; ; ; ; ; ; ; ;
2025
BioMed Central
London
This record in other databases: 
Please use a persistent id in citations: doi:10.1186/s13014-025-02707-7
Abstract: Proprietary bi-nuclide plaques combine the radiation properties of beta and gamma brachytherapy and can irradiate a larger target volume compared to ruthenium-plaques. While reducing the dose to structures outside the target volume, brachytherapy with bi-nuclide-plaques (BBNP) delivers a higher target dose compared to iodine-plaques. We aimed at analyzing the local tumor control and eye retention probability after BBNP.All consecutive cases with large uveal melanoma (tumor thickness ≥ 7 mm) treated with BBNP at our institution between 01/1999 and 12/2020 were included (n = 576, median follow-up: 30.8 months [interquartile range, IQR: 12.9-57.4]). Univariable and multivariable Cox regression analyses were performed.Secondary enucleation (SE) was performed in 13.5% of cases (n = 78) after the median of 20.0 months (IQR: 9.0-34.7) post-BBNP. The overall rate of local tumor recurrence (LR) in the cohort was 8.5% (n = 49) and was diagnosed at the median post-BBNP interval of 20.0 months (IQR: 15.6-35.2). Of the patients' baseline characteristics, higher age (> 67 years, adjusted hazard ratio [aHR] = 1.80, p = 0.011), tumor thickness (> 8.5 mm, aHR = 2.20, p = 0.002), visual acuity (> 0.5 logMAR, aHR = 1.83, p = 0.009), and sclera dose (> 1000 Gy, aHR = 1.65, p = 0.034) were independently associated with the risk of SE. In turn, higher age (> 67 years, aHR = 1.93, p = 0.023), tumor thickness (> 8.5 mm, aHR = 2.02, p = 0.020), and visual acuity (> 0.5 logMAR, aHR = 2.27, p = 0.005) were independently related to LR.BBNP facilitates eye retention in 86.5% of patients with large uveal melanoma 2.5 years after treatment. Patients' baseline, tumor and treatment characteristics were strongly associated with the risk of SE and LR after BBNP.
Keyword(s): Humans (MeSH) ; Brachytherapy: methods (MeSH) ; Uveal Neoplasms: radiotherapy (MeSH) ; Uveal Neoplasms: pathology (MeSH) ; Melanoma: radiotherapy (MeSH) ; Melanoma: pathology (MeSH) ; Male (MeSH) ; Iodine Radioisotopes: therapeutic use (MeSH) ; Uveal Melanoma (MeSH) ; Female (MeSH) ; Middle Aged (MeSH) ; Ruthenium Radioisotopes: therapeutic use (MeSH) ; Aged (MeSH) ; Retrospective Studies (MeSH) ; Adult (MeSH) ; Follow-Up Studies (MeSH) ; Aged, 80 and over (MeSH) ; Neoplasm Recurrence, Local: pathology (MeSH) ; Radiotherapy Dosage (MeSH) ; Prognosis (MeSH) ; Bi-nuclide plaque ; Brachytherapy ; Enucleation ; Local recurrence ; Risk factors ; Uveal melanoma ; Iodine Radioisotopes ; Ruthenium Radioisotopes ; Iodine-125 ; Ruthenium-106
; 
; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
